PhD
University of Virginia, Charlottesville, VA
BA
Keio University, Tokyo, Japan
Naoko Ronquest, PhD, is an Executive Director of US HTA Strategy and Early Modeling in the Health Economics Group at RTI-HS. With over 15 years of experience in health economics and outcomes research (HEOR), she has a robust methodological background in developing pharmacoeconomic models across a range of therapeutic areas.
Dr. Ronquest is well-versed in formulating evidence generation strategies and utilizing HEOR evidence to prepare for health technology assessments including Institute for Clinical and Economic Review (ICER) evaluations and reimbursement submissions in global markets. Her work integrates HEOR considerations into clinical trials and synthesizes clinical and economic evidence to demonstrate the value of pharmaceutical products. She regularly collaborates with large interdisciplinary teams of clinicians, epidemiologists, statisticians, economists, and commercial leaders to design health economic models and present research findings at professional meetings.
Dr. Ronquest has published extensively in peer-reviewed journals and has research experience in numerous therapeutic areas including oncology, cardiovascular diseases, gastrointestinal disorders, neurodegenerative diseases, obesity, ophthalmology, autoimmune disorders, and infectious diseases among others. Additionally, Dr. Ronquest teaches ISPOR’s short courses on country-adaptation and US value assessment framework course.